Intrapleural streptokinase does not improve outcomes in empyema

Menon, M.
June 2005
Thorax;Jun2005, Vol. 60 Issue 6, p450
Academic Journal
The article presents a study which found that intrapleural streptokinase does not improve outcomes in empyema. Intrapleural fibrinolytic agents have been advocated in the management of pleural infection in many respiratory society guidelines. However, the evidence base for this recommendation stems from case series and small trials which do not have adequate statistical power. The MIST1 study was a double blind, randomized, controlled trial with 454 patients enrolled in 52 centres in Great Britain. Statistical analysis was performed on 430 subjects.


Related Articles

  • A study of empyema thoracis and role of intrapleural streptokinase in its management. Banga, Amit; Khilnani, G. C.; Sharma, S. K.; Dey, A. B.; Wig, Naveet; Banga, Namrata // BMC Infectious Diseases;2004, Vol. 4 Issue 1, p19 

    Background: Clinical spectrum, microbiology and outcome of empyema thoracis are changing. Intrapleural instillation of fibrinolytic agents is being increasingly used for management of empyema thoracis. The present study was carried out to describe the clinical profile and outcome of patients...

  • Komplike Parapnæmonik Plevral Efüzyon ve Ampiyemde Ä°ntraplevral Streptokinaz EtkinliÄŸi. Okumuş, N. Gülfer; Karaosman, Sinem; Kıyan, Esen; İşsever, Halim; Arseven, Orhan // Turk Toraks Dergisi / Turkish Thoracic Journal;Mar2010, Vol. 11 Issue 1, p10 

    Objective: Parapneumonic pleural effusions show a wide range, from minimal-uncomplicated pleural effusions to complicated effusions and empyema. At the present time, the use and benefit of intrapleural streptokinase in complicated cases, in addition to closed chest tube drainage and...

  • Impact of a patient decision aid on care among patients with nonvalvular atrial fibrillation: a cluster randomized trial. McAlister, Finlay A.; Man-Son-Hing, Malcolm; Straus, Sharon E.; Ghali, William A.; Anderson, David; Majumdar, Sumit R.; Gibson, Paul; Cox, Jafna L.; Fradette, Miriam // CMAJ: Canadian Medical Association Journal;8/30/2005, Vol. 173 Issue 5, p496 

    Background Too few patients with nonvalvular atrial fibrillation (NVAF) receive appropriate antithrombotic therapy. We tested the short-term (primary outcome) and long-term (secondary outcome) effect of a patient decision aid on the appropriateness of antithrombotic therapy among patients with...

  • Thrombolysis for ischaemic stroke: impact of the extension of the time-window in daily practice. Mihout, Marie; Cordonnier, Charlotte; Girard-Buttaz, Isabelle; Leys, Didier // Journal of Neurology, Neurosurgery & Psychiatry;Feb2012, Vol. 83 Issue 2, p227 

    The article discusses a study which examined how the results of European Cooperative Acute Stroke Study (ECASS)-3 have impacted the practice of treating patients with acute cerebral ischaemia. Previously, it was shown that intravenous recombinant tissue plasminogen activator (rt-PA) administered...

  • Antiplatelet drug offers alternative to aspirin for reducing ischemic events.  // Geriatrics;Dec96, Vol. 51 Issue 12, p21 

    Details the phase-III clinical trials of the antiplatelet drug Clopidogrel. Safety and efficacy profile; Ability to prevent the risk of endpoint ischemic stroke; Review of concomitant hematologic effects.

  • The Effect of Streptokinase Neutralizing Antibodies on Thrombolytic Activity in Double Lumen Cuffed Cat. Atapour, Abdolamir; Hashemi, Noushin; Shahidi, Shahrzad; khandan, Afsaneh // Journal of Isfahan Medical School;10/3/2011, Vol. 29 Issue 149, p1 

    Background: Streptokinase is the only available thrombolytic agent in some areas. Streptococcal infection induces streptococcal antibodies and these antibodies increase failure rate in response to Streptokinase. This study was designed to investigate the effect of neutralizing antibodies on...

  • EXPERIENCE WITH FIBRINOLYTIC THERAPY OF VASCULAR OCCLUSIVE DISEASE. Warner, W. L. // Vascular Surgery;Nov/Dec1977, Vol. 11 Issue 6, p364 

    1. There may well be a place for streptokinase therapy in selected patients with chronic arterial occlusion, but the emphasis should be on developing information on selection criteria. 2. Efficacy and safety have been established for the use of streptokinase in occluded AV cannulae, but this may...

  • Multicenter Trials of Treatment for Empyema – After All These Years. Heffner, John E. // New England Journal of Medicine;3/3/2005, Vol. 352 Issue 9, p926 

    The article focuses on the lack of evidence concerning treatment for empyema. As stated, with the absence of high-quality trials, suggestions for managing pleural infections have relied on pathophysiological observations, small studies, and expert opinion. In this context, a multicenter study...

  • Favourable follow-up for abciximab in ISAR-REACT 2. Pinn, Stephen // British Journal of Hospital Medicine (17508460);Mar2008, Vol. 69 Issue 3, p128 

    The article reports on the findings from Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 (ISAR-REACT 2) clinical trial investigators concerning the adverse events occur with abciximab. It stated that patients with non-ST-segment elevation (NSTE)...


Read the Article


Sign out of this library

Other Topics